We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Transcatheter Mitral Valve Repair Reduces Hospitalization, Improves Survival in Heart Failure Patients

By HospiMedica International staff writers
Posted on 07 Mar 2023
Print article
Image: The MitraClip system is the leading therapy to treat leaky valves in people with mitral regurgitation (Photo courtesy of Abbott)
Image: The MitraClip system is the leading therapy to treat leaky valves in people with mitral regurgitation (Photo courtesy of Abbott)

Left ventricular cardiomyopathy is the most common type of heart failure in which the heart’s main chamber (the left ventricle) becomes enlarged and incapable of properly pumping blood out of the heart. Approximately Roughly 30% of patients with left ventricular cardiomyopathy go on to develop a secondary heart condition called severe mitral valve regurgitation. In this heart condition, the mitral valve, which controls the flow of blood from the left atrium into the left ventricle, becomes distorted from the enlarged left ventricle, resulting in its leaflets failing to close completely. This leads to blood leaking backwards, increasing pressure in the heart, and increasing the patient’s risk of hospitalization and death. In most cases, it is possible to treat this condition with a minimally invasive procedure called transcatheter edge-to-edge repair (TEER) that involves clipping the leaflets of the mitral valve together. The procedure is usually performed with a device called the MitraClip, manufactured by Abbott (Abbott Park, IL, USA)

Breakthrough findings from a new study led by the Icahn School of Medicine at Mount Sinai (New York City, NY, USA) suggest that the utilization of transcatheter mitral valve repair in heart failure patients with mitral regurgitation can lower the long-term hospitalization rate by almost 50% and reduce the risk of death by nearly 30% compared to heart failure patients who do not undertake the minimally invasive procedure. This multi-center trial is the largest trial to examine the safety and effectiveness of transcatheter mitral-valve repair in a heart failure population using Abbott’s MitraClip system. It shows the treatment option can significantly improve patient outcomes in those with heart failure who do not respond to conventional treatments.

In the “Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Device” study, or COAPT, researchers examined whether treating the severe secondary mitral valve regurgitation with TEER, which has no direct effect on the underlying weakened heart muscle, can improve outcomes in heart failure patients beyond medical therapy alone. The two-year results, published in 2018, showed for the first time that treating secondary mitral valve regurgitation improved patients’ symptoms, reduced hospitalizations, and led them to live longer. Now, their latest five-year results show further significant findings.

The study examined 614 patients recruited between December 27, 2012, and June 23, 2017, from 78 centers in the U.S. and Canada. All patients suffered from cardiomyopathy and secondary, severe mitral valve regurgitation, despite receiving optimal medical therapy for heart failure. Half of the patients continued their heart failure medication, while the other half underwent transcatheter valve repair involving the MitraClip, but continued with their heart failure medication. Over the course of five years following treatment, the annual rates of heart failure hospitalizations were found to be 33.1% in the MitraClip group compared to 57.2% in patients treated only with medication, signifying a 47% reduction. Moreover, there was a 29% decrease in deaths from heart failure in the MitraClip group compared to patients taking medication only, and a 28% reduction in all-cause death. Despite having decreased rates of hospitalizations and deaths with successful treatment, 73.6% of patients in the MitraClip group still experienced one or more heart failure hospitalizations or died at the end of five years (compared to 91.5% of patients in the medication-only group). Therefore, the researchers have emphasized the need for advanced therapies to treat these high-risk patients.

“Treating severe secondary mitral regurgitation in appropriate patients with cardiomyopathy is important - our study shows that five years after the MitraClip procedure, patients feel better, are hospitalized less frequently, and live longer,” said lead author Gregg W. Stone, MD, Director of Academic Affairs for the Mount Sinai Health System and Professor of Medicine (Cardiology), and Population Health Science and Policy, at Icahn Mount Sinai. “It’s critical for physicians to recognize mitral regurgitation in patients with cardiomyopathy, then treat this secondary issue as early as possible to improve outcomes in this heart failure group.”

Related Links:
Icahn School of Medicine at Mount Sinai 

Gold Supplier
12-Channel ECG
Ventilator Breathing System
Single-Use Ventilator Breathing Systems
Mobile DR System
uDR 380i Pro

Print article



view channel
Image: The WHO has conditionally recommended the use of algorithms in assisting with pediatric tuberculosis diagnosis (Photo courtesy of Pexels)

New Evidence-Based Algorithms Could Improve Diagnosis of Pediatric Tuberculosis

Tuberculosis (TB) continues to be one of the most prevalent causes of death among younger populations worldwide. Research indicates that over 96% of the deadly TB cases in children under the age of 15... Read more

Surgical Techniques

view channel
Image: Robotic bronchoscopy is used to biopsy lung nodules to detect the presence of lung cancer (Photo courtesy of Pexels)

Robotic Bronchoscopy Enables Doctors to Biopsy Lung Nodules from Hard-to-Reach Areas

Bronchoscopy is a procedure commonly used to diagnose lung cancer and other lung diseases by biopsying lung nodules. Traditional bronchoscopy involves a doctor manually guiding a thin tube, known as a... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more


view channel
Image: The demand for endometrial ablation devices is increasing due to rising prevalence of gynecological disorders (Photo courtesy of Pexels)

Global Endometrial Ablation Market Driven by Rising Prevalence of Gynecological Disorders

Gynecological disorders, such as menorrhagia, PCOD, abnormal vaginal bleeding, affect millions of women globally every year and are on the rise. Abnormal Uterine Bleeding (AUB) is the most common disorder... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.